Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) insider Nelson Sun sold 14,754 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $5.00, for a total transaction of $73,770.00. Following the completion of the sale, the insider owned 97,475 shares in the company, valued at $487,375. The trade was a 13.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Nelson Sun also recently made the following trade(s):
- On Friday, September 11th, Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00.
Aardvark Therapeutics Price Performance
Shares of AARD opened at $5.13 on Monday. Aardvark Therapeutics, Inc. has a 52 week low of $3.35 and a 52 week high of $17.94. The stock’s 50-day moving average price is $6.29 and its 200-day moving average price is $5.48. The company has a market capitalization of $112.24 million, a price-to-earnings ratio of -1.60 and a beta of 3.74.
Aardvark Therapeutics News Summary
Here are the key news stories impacting Aardvark Therapeutics this week:
- Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
- Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
- Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
- Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
- Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert
Analysts Set New Price Targets
AARD has been the topic of several recent analyst reports. Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. Wall Street Zen upgraded Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reissued a “neutral” rating and issued a $6.00 price target on shares of Aardvark Therapeutics in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $15.33.
Check Out Our Latest Research Report on AARD
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Aardvark Therapeutics during the second quarter worth $42,000. Persistent Asset Partners Ltd acquired a new position in Aardvark Therapeutics in the fourth quarter valued at approximately $56,000. New York State Common Retirement Fund purchased a new position in Aardvark Therapeutics in the second quarter worth approximately $99,000. MetLife Investment Management LLC acquired a new stake in Aardvark Therapeutics during the fourth quarter worth $102,000. Finally, Bank of America Corp DE increased its stake in Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after acquiring an additional 3,369 shares during the last quarter.
About Aardvark Therapeutics
Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.
The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.
Featured Articles
- Five stocks we like better than Aardvark Therapeutics
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
